BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10586390)

  • 1. Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies.
    Chen CL; Levine A; Rao A; O'Neill K; Messinger Y; Myers DE; Goldman F; Hurvitz C; Casper JT; Uckun FM
    J Clin Pharmacol; 1999 Dec; 39(12):1248-55. PubMed ID: 10586390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor.
    Uckun FM; Messinger Y; Chen CL; O'Neill K; Myers DE; Goldman F; Hurvitz C; Casper JT; Levine A
    Clin Cancer Res; 1999 Dec; 5(12):3906-13. PubMed ID: 10632319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates.
    Messinger Y; Yanishevski Y; Ek O; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
    Clin Cancer Res; 1998 Jan; 4(1):165-70. PubMed ID: 9516966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate.
    Ek O; Yanishevski Y; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
    Leuk Lymphoma; 1998 Jul; 30(3-4):389-94. PubMed ID: 9713969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cells.
    Myers DE; Jun X; Waddick KG; Forsyth C; Chelstrom LM; Gunther RL; Tumer NE; Bolen J; Uckun FM
    Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9575-9. PubMed ID: 7568175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma.
    Myers DE; Sicheneder A; Clementson D; Dvorak N; Venkatachalam T; Sev AR; Chandan-Langlie M; Uckun FM
    Leuk Lymphoma; 1998 Apr; 29(3-4):329-38. PubMed ID: 9684930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases.
    Uckun FM; Evans WE; Forsyth CJ; Waddick KG; Ahlgren LT; Chelstrom LM; Burkhardt A; Bolen J; Myers DE
    Science; 1995 Feb; 267(5199):886-91. PubMed ID: 7531365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia.
    Darwish M; Megason G; Bond M; Hellriegel E; Robertson P; Grasela T; Phillips L
    Curr Med Res Opin; 2014 Nov; 30(11):2305-15. PubMed ID: 25105914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.
    Meany HJ; Seibel NL; Krailo M; Villaluna D; Chen Z; Gaynon P; Neglia JP; Park JR; Hutchinson R; Sato JK; Wells RJ; Woods WG; Reaman G
    J Immunother; 2015 Sep; 38(7):299-305. PubMed ID: 26261894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
    Zhu M; Wu B; Brandl C; Johnson J; Wolf A; Chow A; Doshi S
    Clin Pharmacokinet; 2016 Oct; 55(10):1271-1288. PubMed ID: 27209293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
    Bonate PL; Cunningham CC; Gaynon P; Jeha S; Kadota R; Lam GN; Razzouk B; Rytting M; Steinherz P; Weitman S
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):875-90. PubMed ID: 20582417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Garrett M; Ruiz-Garcia A; Parivar K; Hee B; Boni J
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):211-222. PubMed ID: 30859374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy.
    Li Q; Hudson W; Wang D; Berven E; Uckun FM; Kersey JH
    Cancer Immunol Immunother; 1998 Nov; 47(3):121-30. PubMed ID: 9829837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.
    Uckun FM; Yanishevski Y; Tumer N; Waurzyniak B; Messinger Y; Chelstrom LM; Lisowski EA; Ek O; Zeren T; Wendorf H; Langlie MC; Irvin JD; Myers DE; Fuller GB; Evans W; Gunther R
    Clin Cancer Res; 1997 Mar; 3(3):325-37. PubMed ID: 9815689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
    Kearns CM; Blakley RL; Santana VM; Crom WR
    Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
    Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
    Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia.
    Li Y; Ramírez-Valle F; Xue Y; Ventura JI; Gouedard O; Mei J; Takeshita K; Palmisano M; Zhou S
    J Clin Pharmacol; 2017 Oct; 57(10):1279-1289. PubMed ID: 28543084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
    Mross K; Holländer N; Frost A; Unger C; Ziroli V; Massing U
    Onkologie; 2006 Oct; 29(10):444-50. PubMed ID: 17028453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.